You are here: Industry Insights > NRx

News List

NRx and MannKind to develop Zyesami inhaler for respiratory ailments pharmaceutical-technology
August 05, 2021
NRx Pharmaceuticals has entered an agreement with MannKind to create a dry powder formulation of its investigational drug, Zyesami (aviptadil), for the treatment of various respiratory ailments.
NRx Pharmaceuticals and Quantum Leap With Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ americanpharmaceuticalreview
July 14, 2021
NRx Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative™ have begun treating patients with inhaled ZYESAMIÔ (Aviptadil), in the I-SPY COVID Trial (NCT04488081), a phase 2 adaptive platform trial aimed at improving treatment for severely ...
NRx and Israel partner to advance Covid-19 vaccine development pharmaceutical-technology
July 13, 2021
NRx Pharmaceuticals has entered a memorandum of understanding with the Government of Israel to licence exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife.
NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI (Aviptadil-acetate) Trial in the Nation of Georgia firstwordpharma
July 07, 2021
NRx Pharmaceuticals (Nasdaq: NRXP) today announced it is initiating clinical training of Nation of Georgia (Georgia) ICU physicians, in the use of intravenous ZYESAMI™ (Aviptadil- acetate) for emergency use in patients suffering with Critical COVID-19.
NRx Pharmaceuticals’ Zyesami yields positive data in EAP for Covid-19 pharmaceutical-technology
June 17, 2021
NRx Pharmaceuticals has reported positive results from the expanded access protocol (EAP) of its Zyesami (Aviptadil) in critical Covid-19 patients admitted to the ICU with respiratory failure.
NRx Pharmaceuticals seeks FDA EUA for Covid-19 therapy Zyesami pharmaceutical-technology
June 03, 2021
NRx Pharmaceuticals has submitted an application to the US Food and Drug Administration (FDA) seeking Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for the treatment of critically ill Covid-19 patients with respiratory failure.